0001127602-20-001661.txt : 20200115 0001127602-20-001661.hdr.sgml : 20200115 20200115171553 ACCESSION NUMBER: 0001127602-20-001661 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200113 FILED AS OF DATE: 20200115 DATE AS OF CHANGE: 20200115 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Gerberding Julie L. CENTRAL INDEX KEY: 0001628884 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-06571 FILM NUMBER: 20528876 MAIL ADDRESS: STREET 1: 2000 GALLOPING HILL ROAD CITY: KENILWORTH STATE: NJ ZIP: 07033 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Merck & Co., Inc. CENTRAL INDEX KEY: 0000310158 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 221918501 STATE OF INCORPORATION: NJ FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2000 GALLOPING HILL ROAD CITY: KENILWORTH STATE: NJ ZIP: 07033 BUSINESS PHONE: 908-740-4000 MAIL ADDRESS: STREET 1: 2000 GALLOPING HILL ROAD CITY: KENILWORTH STATE: NJ ZIP: 07033 FORMER COMPANY: FORMER CONFORMED NAME: Merck & Co. Inc. DATE OF NAME CHANGE: 20091103 FORMER COMPANY: FORMER CONFORMED NAME: SCHERING PLOUGH CORP DATE OF NAME CHANGE: 19920703 4 1 form4.xml PRIMARY DOCUMENT X0306 4 2020-01-13 0000310158 Merck & Co., Inc. MRK 0001628884 Gerberding Julie L. MERCK & CO., INC. 2000 GALLOPING HILL ROAD KENILWORTH NJ 07033 1 EVP Strat Comm, GI Pub Policy Common Stock 2020-01-13 4 M 0 49536 0 A 106099.366 D Common Stock 2020-01-13 4 M 0 33012 0 A 139111.366 D Common Stock 2020-01-13 4 S 0 102073 89.3367 D 37038.366 D Stock Option (Right to Buy) 59.86 2020-01-13 4 M 0 49536 0 D 2016-05-01 2025-04-30 Common Stock 49536 0 D Stock Option (Right to Buy) 58.22 2020-01-13 4 M 0 33012 0 D 2015-05-02 2024-05-01 Common Stock 33012 0 D The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.04 to $89.61, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Holdings include shares acquired in dividend reinvestment transactions. The option became exercisable in equal installments on 5/1/2016, 5/1/2017 and 5/1/2018. The option became exercisable in equal installments on 5/2/2015, 5/2/2016 and 5/2/2017. Faye C. Brown as Attorney-in-Fact for Julie L. Gerberding 2020-01-15